Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rozzano – page 175

2 815 clinical trials in Rozzano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rozzano at a glance
2 815
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 815 trials in Rozzano

Open in trial search

Autoimmune haemolytic anaemia

Not recruiting

Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastric cancer

Not recruiting

Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Evorpacept
  • Sponsor:Alx Oncology Holdings Inc.

B-cell lymphoma+1

Not recruiting

Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Englumafusp Alfa
  • Sponsor:F. Hoffmann-La Roche AG

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic hepatitis B

Not recruiting

Long-term Study on Treatment Response in Chronic Hepatitis B Patients Using Bepirovirsen

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Prostate cancer metastatic

Not recruiting

Study on the Safety and Effects of AZD5305 with Hormonal Agents for Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Atypical haemolytic uraemic syndrome

Not recruiting

Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study of Tobemstomig with Platinum-Based Chemotherapy vs Pembrolizumab with Platinum-Based Chemotherapy for Untreated Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer metastatic

Not recruiting

Study on the Effectiveness of Apalutamide in Men with Castration-Resistant Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Aragon Pharmaceuticals Inc.

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Rozzano

What the registry says about research in the country

01 Oncology Research

Critical investigations focusing on various cancer types including metastatic colorectal cancer, acute myeloid leukemia, and advanced breast cancer. Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

  • Gastric and Gastroesophageal Cancer Treatments
  • Breast Cancer Therapies
  • Blood Cancer Interventions

Multiple trials exploring innovative treatment approaches for both solid tumors and hematological malignancies.

02 Respiratory and Pulmonary Studies

Research initiatives examining treatments for idiopathic pulmonary fibrosis and chronic respiratory conditions. Studies focus on improving lung function and patient quality of life.

  • Pulmonary Fibrosis Management
  • Chronic Rhinosinusitis Treatment

Investigations aim to advance therapeutic options for patients with chronic respiratory conditions.

03 Autoimmune and Inflammatory Diseases

Comprehensive research into conditions like psoriatic arthritis and systemic sclerosis. Studies evaluate new biological treatments and therapeutic approaches.

  • Inflammatory Bowel Diseases
  • Skin and Joint Conditions
  • Immune System Disorders

Trials focus on developing targeted therapies for various inflammatory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.